POSB19 Matching-Adjusted Indirect Comparison of Trastuzumab Deruxtecan vs. Eribulin, Capecitabine, and Vinorelbine for Treating Human Epidermal Growth Factor Receptor 2-Positive Unresectable or Metastatic Breast Cancer after Two or More Anti-Human Epidermal Growth Factor Receptor 2-Positive Therapies

Autor: Dunton, K, Vondeling, G, Paine, A
Zdroj: In Value in Health January 2022 25(1) Supplement:S28-S28
Databáze: ScienceDirect
Externí odkaz: